vs

Side-by-side financial comparison of Legence Corp. (LGN) and West Pharmaceutical Services (WST). Click either name above to swap in a different company.

West Pharmaceutical Services is the larger business by last-quarter revenue ($805.0M vs $708.0M, roughly 1.1× Legence Corp.). West Pharmaceutical Services runs the higher net margin — 16.4% vs -0.1%, a 16.5% gap on every dollar of revenue. On growth, Legence Corp. posted the faster year-over-year revenue change (26.2% vs 7.5%). West Pharmaceutical Services produced more free cash flow last quarter ($175.0M vs $137.4M).

Legence Corp is a leading sustainable building and decarbonization solution provider. It delivers energy efficiency optimization, building automation design, renewable energy integration, and low-carbon retrofit services for commercial, industrial, and institutional clients, with core operations across North America to help customers cut costs and reduce carbon footprints.

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin.

LGN vs WST — Head-to-Head

Bigger by revenue
WST
WST
1.1× larger
WST
$805.0M
$708.0M
LGN
Growing faster (revenue YoY)
LGN
LGN
+18.7% gap
LGN
26.2%
7.5%
WST
Higher net margin
WST
WST
16.5% more per $
WST
16.4%
-0.1%
LGN
More free cash flow
WST
WST
$37.6M more FCF
WST
$175.0M
$137.4M
LGN

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LGN
LGN
WST
WST
Revenue
$708.0M
$805.0M
Net Profit
$-576.0K
$132.1M
Gross Margin
20.9%
37.8%
Operating Margin
5.3%
19.5%
Net Margin
-0.1%
16.4%
Revenue YoY
26.2%
7.5%
Net Profit YoY
46.8%
1.5%
EPS (diluted)
$-0.02
$1.82

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LGN
LGN
WST
WST
Q4 25
$805.0M
Q3 25
$708.0M
$804.6M
Q2 25
$766.5M
Q1 25
$698.0M
Q4 24
$748.8M
Q3 24
$560.8M
$746.9M
Q2 24
$702.1M
Q1 24
$695.4M
Net Profit
LGN
LGN
WST
WST
Q4 25
$132.1M
Q3 25
$-576.0K
$140.0M
Q2 25
$131.8M
Q1 25
$89.8M
Q4 24
$130.1M
Q3 24
$-1.1M
$136.0M
Q2 24
$111.3M
Q1 24
$115.3M
Gross Margin
LGN
LGN
WST
WST
Q4 25
37.8%
Q3 25
20.9%
36.6%
Q2 25
35.7%
Q1 25
33.2%
Q4 24
36.5%
Q3 24
21.1%
35.4%
Q2 24
32.8%
Q1 24
33.1%
Operating Margin
LGN
LGN
WST
WST
Q4 25
19.5%
Q3 25
5.3%
20.8%
Q2 25
20.1%
Q1 25
15.3%
Q4 24
21.3%
Q3 24
4.8%
21.6%
Q2 24
18.0%
Q1 24
17.7%
Net Margin
LGN
LGN
WST
WST
Q4 25
16.4%
Q3 25
-0.1%
17.4%
Q2 25
17.2%
Q1 25
12.9%
Q4 24
17.4%
Q3 24
-0.2%
18.2%
Q2 24
15.9%
Q1 24
16.6%
EPS (diluted)
LGN
LGN
WST
WST
Q4 25
$1.82
Q3 25
$-0.02
$1.92
Q2 25
$1.82
Q1 25
$1.23
Q4 24
$1.78
Q3 24
$1.85
Q2 24
$1.51
Q1 24
$1.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LGN
LGN
WST
WST
Cash + ST InvestmentsLiquidity on hand
$176.0M
$791.3M
Total DebtLower is stronger
$812.6M
$202.8M
Stockholders' EquityBook value
$387.9M
$3.2B
Total Assets
$2.6B
$4.3B
Debt / EquityLower = less leverage
2.10×
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LGN
LGN
WST
WST
Q4 25
$791.3M
Q3 25
$176.0M
$628.5M
Q2 25
$509.7M
Q1 25
$404.2M
Q4 24
$484.6M
Q3 24
$490.9M
Q2 24
$446.2M
Q1 24
$601.8M
Total Debt
LGN
LGN
WST
WST
Q4 25
$202.8M
Q3 25
$812.6M
$202.7M
Q2 25
$202.6M
Q1 25
$202.6M
Q4 24
$202.6M
Q3 24
$202.6M
Q2 24
$205.8M
Q1 24
$206.2M
Stockholders' Equity
LGN
LGN
WST
WST
Q4 25
$3.2B
Q3 25
$387.9M
$3.1B
Q2 25
$2.9B
Q1 25
$2.7B
Q4 24
$2.7B
Q3 24
$2.8B
Q2 24
$2.6B
Q1 24
$2.7B
Total Assets
LGN
LGN
WST
WST
Q4 25
$4.3B
Q3 25
$2.6B
$4.1B
Q2 25
$4.0B
Q1 25
$3.6B
Q4 24
$3.6B
Q3 24
$3.7B
Q2 24
$3.5B
Q1 24
$3.6B
Debt / Equity
LGN
LGN
WST
WST
Q4 25
0.06×
Q3 25
2.10×
0.07×
Q2 25
0.07×
Q1 25
0.08×
Q4 24
0.08×
Q3 24
0.07×
Q2 24
0.08×
Q1 24
0.08×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LGN
LGN
WST
WST
Operating Cash FlowLast quarter
$162.1M
$251.1M
Free Cash FlowOCF − Capex
$137.4M
$175.0M
FCF MarginFCF / Revenue
19.4%
21.7%
Capex IntensityCapex / Revenue
3.5%
9.5%
Cash ConversionOCF / Net Profit
1.90×
TTM Free Cash FlowTrailing 4 quarters
$468.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LGN
LGN
WST
WST
Q4 25
$251.1M
Q3 25
$162.1M
$197.2M
Q2 25
$177.1M
Q1 25
$129.4M
Q4 24
$190.1M
Q3 24
$180.1M
Q2 24
$165.0M
Q1 24
$118.2M
Free Cash Flow
LGN
LGN
WST
WST
Q4 25
$175.0M
Q3 25
$137.4M
$133.9M
Q2 25
$101.9M
Q1 25
$58.1M
Q4 24
$85.2M
Q3 24
$98.8M
Q2 24
$64.8M
Q1 24
$27.6M
FCF Margin
LGN
LGN
WST
WST
Q4 25
21.7%
Q3 25
19.4%
16.6%
Q2 25
13.3%
Q1 25
8.3%
Q4 24
11.4%
Q3 24
13.2%
Q2 24
9.2%
Q1 24
4.0%
Capex Intensity
LGN
LGN
WST
WST
Q4 25
9.5%
Q3 25
3.5%
7.9%
Q2 25
9.8%
Q1 25
10.2%
Q4 24
14.0%
Q3 24
10.9%
Q2 24
14.3%
Q1 24
13.0%
Cash Conversion
LGN
LGN
WST
WST
Q4 25
1.90×
Q3 25
1.41×
Q2 25
1.34×
Q1 25
1.44×
Q4 24
1.46×
Q3 24
1.32×
Q2 24
1.48×
Q1 24
1.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LGN
LGN

Installation And Fabrication$408.7M58%
Engineering And Design$110.9M16%
Program And Project Management$101.2M14%
Maintenance And Service$87.1M12%

WST
WST

Proprietary Products$661.8M82%
Contract Manufactured Products$143.2M18%
Affiliated Entity$3.3M0%

Related Comparisons